Gynecologic Oncology Reports最新文献

{"title":"Identifying and capitalizing on unique molecular alterations of mucinous ovarian carcinoma for the development of novel therapeutic strategies","authors":"Minyoung Jang,&nbsp;Stefan Gysler,&nbsp;Nawar A. Latif,&nbsp;Emily M. Ko,&nbsp;Robert L. Giuntoli II,&nbsp;Sarah H. Kim,&nbsp;Fiona Simpkins,&nbsp;Dimitrios Nasioudis","doi":"10.1016/j.gore.2025.102008","DOIUrl":"10.1016/j.gore.2025.102008","url":null,"abstract":"<div><h3>Objective</h3><div>Mucinous ovarian carcinoma (MOC) is a rare histologic subtype of ovarian cancer. While prognosis of early stage disease is excellent, novel treatment options are needed for advanced stage and recurrent MOC, which are associated with poor oncologic outcomes. In this context, we aimed to investigate the genomic profile of MOC and characterize the prevalence of actionable genomic alterations.</div></div><div><h3>Methods</h3><div>The American Association of Cancer Research Genomics Evidence of Neoplasia Information Exchange was accessed, and patients with mucinous ovarian, appendiceal and colorectal carcinoma were identified. Data from the OncoKB database, as provided by cBioPortal, were utilized to determine the presence of pathogenic gene alterations. When comparing the genomic profile of mucinous ovarian and colorectal or appendiceal carcinoma, to decrease the false discovery rate, a q-value of &lt; 0.05 as derived from the Benjamini-Hochberg FDR correction procedure was deemed statistically significant.</div></div><div><h3>Results</h3><div>A total of 148 patients with MOC contributing to 157 tumor samples were identified. The most commonly observed genetic alterations were in <em>KRAS</em> (69.4 %), <em>TP53</em> (64.3 %), <em>CDKN2A</em> (33.3 %), <em>CDKN2B</em> (24 %), <em>ERBB2</em> (12 %), <em>PIK3CA</em> (9.6 %), and <em>ARID1A</em> (9.0 %). <em>BRCA1</em> (0 %) and <em>BRCA2</em> (2.3 %) mutations were rare. Homologous deletion of chromosome 9p21.3 was present in 34.4 % of patients. Compared to mucinous appendiceal carcinoma (n = 268), MOC is characterized by a higher incidence of <em>TP53</em>, <em>CDKN2A</em>, <em>CDKN2B</em>, and <em>ERBB2</em> and a lower rate of <em>GNAS</em> gene alterations (q &lt; 0.001). Compared to colorectal mucinous adenocarcinoma (n = 358), MOC is characterized by a higher incidence of <em>KRAS</em>, <em>TP53</em>, <em>CDKN2A</em>, <em>CDKN2B</em>, and <em>ERBB2</em> and a lower rate of <em>PIK3CA</em>, <em>KMT2D</em>, <em>SMAD4</em>, <em>BRAF</em>, and <em>APC</em> gene alterations (q &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>MOC has a distinct genomic profile with molecular vulnerabilities that can be exploited using novel targeted therapies. Participation of patients with MOC in molecularly driven early phase basket trials should be encouraged.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102008"},"PeriodicalIF":1.3,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Invasive Acantholytic Extramammary Paget's Disease of the Vulva With Mammary Carcinoma-Like Differentiation and MMR Loss: Report of an Unusual Case and Its Clinical Mimics","authors":"Jessica Claus ,&nbsp;Janina Pearce ,&nbsp;Areta Bojko ,&nbsp;Padmini Manrai ,&nbsp;M.Ruhul Quddus ,&nbsp;Shivali Marketkar","doi":"10.1016/j.gore.2025.102007","DOIUrl":"10.1016/j.gore.2025.102007","url":null,"abstract":"<div><h3>Background</h3><div>Paget’s disease (EMPD) of the vulva primarily affects postmenopausal women and can present significant challenges in early clinical detection.</div><div><strong>Case Presentation:</strong> We report an exceedingly rare case of invasive acantholytic extramammary Paget’s disease in a 78-year-old female patient. After biopsy-proven carcinoma, a radical hemivulvectomy of the left vulva was performed, which revealed an invasive adenocarcinoma, most consistent with primary extramammary Paget’s carcinoma. Histologic examination demonstrated a unique morphology, featuring an in-situ component with suprabasal intraepidermal acantholysis and an invasive component with various morphologies, including basaloid, skin adnexal-like, focal squamoid, and mammary-like differentiation, resembling ductal carcinoma in situ (DCIS) with comedonecrosis and invasive ductal carcinoma. This varied morphology has not been described before. Interestingly, the tumor shows loss of MMR protein (MSH2, MSH6).</div></div><div><h3>Conclusion</h3><div>In the literature, acantholytic Paget’s disease and acantholytic anaplastic Paget’s disease have been used interchangeably. While anaplastic Paget’s disease has been reported in the mammary and extramammary sites (scrotum, esophagus), involvement of the vulva has been reported only once in the literature. However, the current case is the first documented loss of MMR. Both cases presented with invasive disease ranging in depth from 3-5 mm, and positive lymph nodes emphasizing on the urgent need to further explore prognostic factors of this rare entity and to differentiate it from other acantholytic lesions, such as squamous cell carcinoma in situ and other acantholytic dermatoses.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102007"},"PeriodicalIF":1.3,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment delay and prolongation in locally advanced cervical cancer","authors":"Maya Gross ,&nbsp;Joyce Y. Wang ,&nbsp;Barbara A. Goff ,&nbsp;Ting Martin Ma ,&nbsp;Kylie H. Kang ,&nbsp;Kemi M. Doll ,&nbsp;Soledad Jorge","doi":"10.1016/j.gore.2025.102004","DOIUrl":"10.1016/j.gore.2025.102004","url":null,"abstract":"<div><h3>Objectives</h3><div>Prolonged chemoradiation (CRT) duration predicts inferior survival in locally advanced cervical cancer (LACC). Pre-treatment delays and causes of prolonged treatment duration are less characterized. We aimed to quantify delays across the care continuum and identify predictors of delayed CRT initiation and treatment prolongation.</div></div><div><h3>Methods</h3><div>In this retrospective cohort study, we evaluated LACC patients receiving definitive CRT from 2013 to 2024 at an NCI-designated Cancer Center. We assessed care intervals and sociodemographic/clinical variables. Primary outcome was total patient delay (diagnosis to CRT completion), subdivided into delayed treatment initiation (&gt;75th percentile from diagnosis to CRT) and prolonged CRT duration (&gt;56 days). Secondary outcomes included predictors of delay / prolongation (x<strong>²</strong> tests, logistic regression), progression free survival (PFS), and overall survival (OS).</div></div><div><h3>Results</h3><div>Among 92 patients, median time to CRT initiation was 49 days (IQR 40–62) and median treatment duration was 57 days (IQR 52–60). Treatment delay or prolongation was associated with insurance type, external beam radiation therapy (EBRT) at an outside facility, and adenocarcinoma histology (p &lt; 0.05). Time from diagnosis to completion of LACC staging was the interval most predictive of treatment delay (OR 3.7, CI 1.8–7.7). Treatment prolongation was associated with longer intervals between EBRT and brachytherapy (BT) (OR 2.6,CI 1.6–4.2) but not with time to initiate EBRT or EBRT duration. PFS and OS were not associated with primary outcomes.</div></div><div><h3>Conclusions</h3><div>A quarter of patients waited over 2 months to initiate CRT, and half experienced prolonged treatment duration. Delays in staging and transitions in care, especially between institutions, contributed significantly to total patient delay.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102004"},"PeriodicalIF":1.3,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic and therapeutic implications of clinical-radiologic discrepancy in parametrial invasion prior to primary radical hysterectomy in cervical cancer","authors":"Ester P. Olthof ,&nbsp;Nicholai A. Oostveen ,&nbsp;Maaike A. van der Aa ,&nbsp;Ruud L.M. Bekkers ,&nbsp;Constantijne H. Mom ,&nbsp;Jacobus van der Velden ,&nbsp;Joost Nederend ,&nbsp;Edith M.G. van Esch","doi":"10.1016/j.gore.2025.102002","DOIUrl":"10.1016/j.gore.2025.102002","url":null,"abstract":"<div><h3>Aim</h3><div>This study evaluates the prognostic and therapeutic implications of clinical-radiologic discrepancy in parametrial invasion of cervical cancer prior to radical hysterectomy. We compared patients with radiological presence but clinical absence of parametrial invasion (discrepancy group) to those without radiologic and clinical suspicion of parametrial invasion (consensus group).</div></div><div><h3>Methods</h3><div>Women with International Federation of Gynaecology and Obstetrics (2009) stage IA-IIA cervical cancer, diagnosed between 2009 and 2017, who underwent magnetic resonance imaging prior to radical hysterectomy were retrospectively selected from the Netherlands Cancer Registry. Kaplan-Meier estimates and Cox proportional hazards were used for survival and logistic regression for risk of adjuvant therapy and toxicity.</div></div><div><h3>Results</h3><div>Of 886 patients included, 87 (10%) had clinical-radiologic parametrial invasion discrepancy. Patients with discrepancy were more likely to have poor prognostic factors (i.e., a larger tumor, increased depth of invasion, lymphovascular space invasion, nodal metastases and positive resection margins) than those without. The 5-year disease-free and overall survival rates were lower in the discrepancy (74% and 82%) than in the consensus group (86% and 92%). However, after confounder adjustments, disease-free and overall survival were not affected by clinical-radiologic discrepancy. Patients with discrepancy in parametrial invasion were more likely to receive adjuvant therapy (54% vs 23%) and experience therapy-related toxicity (44% vs 29%).</div></div><div><h3>Conclusion</h3><div>Clinical-radiologic discrepancy of parametrial invasion occurs in approximately 10% of patients and is associated with poor prognostic factors and increased likelihood of adjuvant therapy and toxicity. This highlights the importance of addressing these factors in treatment counselling for either primary chemoradiotherapy or surgery.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 102002"},"PeriodicalIF":1.3,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145788035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abdominal wall blocks in robotic hysterectomy for endometrial cancer are associated with a modest reduction in the frequency of patients receiving post-operative intravenous opioids","authors":"Ioana Bondre ,&nbsp;H. Meryem Soylu ,&nbsp;Francesca Corbetta ,&nbsp;Breana Hill ,&nbsp;Elise Wilson ,&nbsp;Rodney Gabriel ,&nbsp;Ramez Eskander ,&nbsp;Michael McHale ,&nbsp;Cheryl Saenz ,&nbsp;Pratibha Binder ,&nbsp;Steven Plaxe","doi":"10.1016/j.gore.2025.101995","DOIUrl":"10.1016/j.gore.2025.101995","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the association of abdominal wall blocks at the time of robotic hysterectomy performed for endometrial cancer (EC) with in-hospital post-operative opioids.</div></div><div><h3>Methods</h3><div>We performed a retrospective cohort study of patients in the Vizient database<!--> <!-->who had robotic hysterectomy for EC between January 2019 and December 2022. The exposure was any<!--> <!-->block coded separate from the surgery, and the primary outcomes were any IV/oral opioid. Fentanyl was excluded due to frequent intra-op<!--> <!-->use. Length of stay (LOS) and<!--> <!-->direct cost<!--> <!-->were compared. The association between block and opioid use<!--> <!-->was assessed via risk ratio. The quantity of each opioid was expressed in standard resource units (SRU) – a metric<!--> <!-->used to standardize the consumption of medications across facilities.</div></div><div><h3>Results</h3><div>Three hundred and twenty of the 9062 patients (3.5 %) had a block and 8,742 (96.5 %) did not. Blocks were performed at 66 (20.4 %) hospitals.<!--> <!-->184 patients (57.5 %) in the block group received an IV opioid vs 5,890 (67.4 %) of the<!--> <!-->patients without a block (RR 0.85, 95 % CI 0.77–0.94, p &lt; 0.001). Patients who received blocks were less likely to receive IV (52.5 % vs 64.8 %, RR 0.81, 95 % CI 0.73–0.89, p &lt; 0.001)<!--> <!-->and oral hydromorphone (6.9 % vs 3.9 %, RR 2.53, 95 % CI 1.68–3.81, p &lt; 0.001)<!--> <!-->and more likely to receive oral hydrocodone/acetaminophen (11.3 % vs 0.88 %, RR 12.77, 95 % CI 8.73–18.67, p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Blocks are infrequently performed and<!--> <!-->are associated with a modest reduction in the number of patients receiving post-op IV opioids.<!--> <!-->We found no difference<!--> <!-->in<!--> <!-->LOS or cost. Limitations include lack of detail regarding type of block, anesthetic, and phase of care.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 101995"},"PeriodicalIF":1.3,"publicationDate":"2025-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145697958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mucinous ovarian neoplasm – outcomes of a rare tumor","authors":"Bahareh Hamedi ,&nbsp;Shilpa Mokshagundam ,&nbsp;Antonio Lembo ,&nbsp;S John Weroha ,&nbsp;Michaela E. McGree ,&nbsp;Amanda L. Tapia ,&nbsp;Carrie L. Langstraat","doi":"10.1016/j.gore.2025.101996","DOIUrl":"10.1016/j.gore.2025.101996","url":null,"abstract":"<div><h3>Background</h3><div>Mucinous epithelial ovarian (mEO) tumors are rare entities. In this study, we describe the management and outcomes of patients treated for mucinous borderline tumor and mucinous adenocarcinoma of the ovary.</div></div><div><h3>Methods</h3><div>This was a retrospective review of patients with mEO tumors from 1988 − 2021 from a single institution database. Primary outcomes were disease recurrence and death within five years post-surgery, evaluated using Cox proportional hazards and Kaplan-Meier survival analysis.</div></div><div><h3>Results</h3><div>We identified 262 patients with mEO tumors with a mean age of 54.9 years. One-hundred and forty-three patients (55 %) had borderline tumors and 119 (45 %) adenocarcinoma. Most patients underwent complete surgical resection (95 %).</div><div>Those with mucinous borderline tumors had favorable prognosis, with 5-year progression-free survival (PFS) and overall survival (OS) of 97%. Among patients with mucinous adenocarcinoma, 5-year PFS was 78% and 5-year OS was 80%. Fifty-seven patients with adenocarcinoma (48%) received adjuvant chemotherapy.</div><div>In univariate analysis, adenocarcinoma histology, residual disease, advanced FIGO stage (II-IV), and receipt of adjuvant chemotherapy were associated with recurrence and death within five years of surgery. While a considerable proportion of patients in both cohorts underwent gastrointestinal (GI) endoscopy, all findings were negative/benign.</div></div><div><h3>Conclusions</h3><div>Mucinous tumors of the ovary have overall favorable survival outcomes. In this cohort, residual disease, histopathology, and receipt of adjuvant chemotherapy were associated with disease recurrence. In addition, GI workup was of limited utility. Further study is needed to clarify ideal adjuvant treatment and GI workup.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101996"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ovarian carcinoid tumor with carcinoid heart syndrome: A case report and literature review","authors":"Minyoung Jang ,&nbsp;Lakeisha Mulugeta-Gordon ,&nbsp;Joseph Carver ,&nbsp;Natalie Tupper ,&nbsp;Julie Barbera ,&nbsp;Lauren Schwartz ,&nbsp;Nawar Latif","doi":"10.1016/j.gore.2025.101997","DOIUrl":"10.1016/j.gore.2025.101997","url":null,"abstract":"<div><h3>Background</h3><div>Primary ovarian carcinoid tumors are rare neuroendocrine neoplasms comprising &lt;0.1% of ovarian tumors and 1% of all carcinoid tumors. Up to 30% present with carcinoid syndrome, and approximately one-quarter of these develop carcinoid heart syndrome. Unlike gastrointestinal carcinoid tumors, ovarian lesions can cause carcinoid syndrome without hepatic metastases due to direct venous drainage into the systemic circulation.</div></div><div><h3>Case</h3><div>A 46-year-old woman presented with abdominal discomfort, new onset hypertension, and lower extremity edema. Imaging revealed a 16.8 cm right adnexal mass with mixed solid and cystic components. Echocardiography demonstrated torrential tricuspid regurgitation related to thickened, immobile leaflets, consistent with carcinoid heart syndrome. Serum serotonin and chromogranin A were markedly elevated. She underwent exploratory laparotomy, total abdominal hysterectomy, bilateral salpingo-oophorectomy, right pelvic and para-aortic lymphadenectomy, and omental biopsy. Pathology showed a carcinoid tumor arising in a mature cystic teratoma, confined to the right ovary (FIGO stage IA). Immunohistochemistry confirmed neuroendocrine differentiation (synaptophysin, chromogranin positive). Postoperatively, chromogranin A normalized, serotonin decreased, and proBNP improved. Three months later, she underwent successful bioprosthetic tricuspid valve replacement with ongoing Cardiology follow up.</div></div><div><h3>Discussion</h3><div>This case illustrates that ovarian carcinoid tumors may present with minimal symptoms despite significant cardiac involvement. Early cardiac evaluation is warranted in suspected carcinoid tumors to identify carcinoid heart syndrome. Overall survival is generally favorable for early stage ovarian carcinoid tumors. Long-term cardiac prognosis is determined by right ventricular function and presence of residual tumor after resection. Management requires individualized and multidisciplinary surgical planning, balancing tumor resection with timely cardiac intervention.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101997"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A fast-progressing orthotopic ovarian cancer model reveals synergistic antitumor effects of AXL-targeting nanobodies and Olaparib","authors":"Aarushi A. Caro ,&nbsp;Alícia Gordún Peiró ,&nbsp;Eva Hadadi ,&nbsp;Yani Berckmans ,&nbsp;Yvon Elkrim ,&nbsp;Ayla Debraekeleer ,&nbsp;Gisèle Mateu Cabrera ,&nbsp;Kim De Veirman ,&nbsp;An Coosemans ,&nbsp;Damya Laoui","doi":"10.1016/j.gore.2025.101998","DOIUrl":"10.1016/j.gore.2025.101998","url":null,"abstract":"<div><h3>Objective</h3><div>Ovarian cancer (OC) is the deadliest gynecological malignancy, with patients experiencing late diagnosis and high recurrence. AXL is highly expressed in OC and correlates with worse prognosis. We aim to evaluate the use of AXL-targeting nanobodies as a novel therapeutic modality to inhibit the AXL-GAS6 axis in OC.</div></div><div><h3>Methods</h3><div>ID8-fLuc cells were <em>in vivo</em> passaged three times to obtain the fast-progressing P3 ID8 Thy1.1 cell line. The expression of AXL in ID8 lines was assessed by flow cytometry and immunofluorescence, while serum GAS6 levels in tumor-bearing and naïve mice were measured by ELISA. Using <em>in silico</em> analyses, we correlated AXL and GAS6 expression with OC patient outcomes and assessed AXL expression in different tissues and patient cohorts. Orthotopic ovarian tumors were processed to a single cell suspension and treated <em>in vitro</em> with the nanobody (AXL-Fc), a PARP inhibitor (Olaparib), or controls (PBS or DMSO) for 24 h or 72 h, followed by flow cytometry to assess stages of cell death and cancer cell proliferation.</div></div><div><h3>Results</h3><div><em>In vivo</em> passaging of ID8-fLuc cells resulted in a faster-progressing P3 ID8 Thy1.1 cell line that recapitulates stages I-III observed in OC patients. In OC patients, <em>AXL</em> and <em>GAS6</em> genes are highly expressed in primary and metastatic tumors, and enriched in platinum-resistant patients. AXL-Fc induces necrosis in OC cells from orthotopic ovarian tumors. AXL-Fc synergizes with Olaparib, resulting in decreased OC cell proliferation.</div></div><div><h3>Conclusions</h3><div>Leveraging the synergistic effects of AXL-Fc with Olaparib, we propose a new AXL-targeting treatment approach for OC that warrants further investigation.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101998"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145620213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Somatically derived ovarian yolk sac tumor in a postmenopausal woman: A case report of durable remission with personalized chemotherapy","authors":"Vinita Popat ,&nbsp;Adam Rucker ,&nbsp;Joseph W. Carlson ,&nbsp;Aimee Keegan ,&nbsp;Lorna Rodriguez-Rodriguez","doi":"10.1016/j.gore.2025.101989","DOIUrl":"10.1016/j.gore.2025.101989","url":null,"abstract":"<div><h3>Background</h3><div>Somatically derived ovarian yolk sac tumors (SD-YSTs) in postmenopausal women are rare and typically present with advanced-stage disease, often carrying a poor prognosis.</div></div><div><h3>Case</h3><div>We describe a 74-year-old woman with stage IIIB SD-YST who underwent complete surgical resection followed by cisplatin-etoposide chemotherapy, with bleomycin omitted due to frailty. Chemotherapy scheduling was modified in real time according to alpha-fetoprotein (AFP) kinetics, with treatment intervals shortened from 21 to 14 days after AFP levels rose between early cycles. Despite dose reductions due to thrombocytopenia, AFP levels normalized after cycle 3, and treatment was discontinued after cycle 4.</div></div><div><h3>Outcome</h3><div>The patient has remained disease-free for over five years with ongoing surveillance.</div></div><div><h3>Conclusion</h3><div>This case underscores the potential for long-term remission in SD-YST with platinum-based therapy, even when standard regimens require modification for older or frail patients. It highlights the value of biomarker-guided treatment adjustments to optimize chemotherapy timing in rare ovarian malignancies.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101989"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145690326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Etoposide combined with anlotinib and sintilimab successfully achieved long term progression-free survival in platinum-refractory ovarian cancer: A case report","authors":"Luying Zhang,&nbsp;Yuxin Wang,&nbsp;Cang Qiu,&nbsp;Yang Li,&nbsp;Kelei Zhao,&nbsp;Xiaohan Yuan,&nbsp;Yanting Liu,&nbsp;Ping Lu,&nbsp;Min Zhang","doi":"10.1016/j.gore.2025.101999","DOIUrl":"10.1016/j.gore.2025.101999","url":null,"abstract":"<div><h3>Background</h3><div>Platinum-refractory ovarian cancer (PROC) is extremely malignant and aggressive. Patients typically have a diminished quality of life and limited survival, with an overall survival<!--> <!-->(OS)<!--> <!-->of less than one year. Until early 2024, bevacizumab remains the only targeted agent approved in China for the treatment of PROC. The standard regimen for PROC in China is non-platinum single-agent chemotherapy, or chemotherapy combined with<!--> <!-->bevacizumab. However, these therapies have not achieved<!--> <!-->satisfactory clinical outcomes.</div></div><div><h3>Case presentation</h3><div>A 63-year-old woman presented with an incidentally detected left neck mass. Ultrasound-guided biopsy revealed high-grade serous ovarian carcinoma. She received first-line bevacizumab plus platinum-based chemotherapy but showed disease progression after two cycles, consistent with platinum-refractory ovarian cancer. After similarly failing second-line gemcitabine therapy (2 cycles), she achieved complete response (CR) and maintained progression-free survival (PFS) for 23.9 months with third-line etoposide combined with anlotinib and sintilimab.</div></div><div><h3>Conclusion</h3><div>This case demonstrates that the combination of etoposide, anlotinib, and sintilimab can induce sustained CR in platinum-refractory ovarian cancer, achieving remarkable 23.9-month PFS. The synergistic activity of this regimen successfully reversed multidrug resistance and may redefine third-line therapeutic strategies for this challenging population.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"62 ","pages":"Article 101999"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145690324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}